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Abstract 
Neonatal rat islets exhibit a reduced secretory response to glucose, compared to adult rat islets. The maturation of the secretory response is 
stimulated by prolactin (PRL). We show here by immunoblot analysis that PRL increases the B-cell/liver glucose transporter GLUT2 in membrane 
fractions from cultured neonatal rat islets. This increase (+86%) may explain, at least in part, the development of a mature glucose response. G proteins 
modulate insulin secretion from pancreatic p-cells. We show here by immunoblot analysis that, in contrast o the effect on GLUTZ, PRL treatment 
does not modify the G protein subunits ai2, ai3, cco, as, ccq and 835 and 836, in cultured neonatal islets. 
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1. Introduction 
Fetal and neonatal rat islets exhibit a reduced secre- 
tory response to glucose, compared to adult rat islets 
[14]. The maturation of the secretory response is influ- 
enced by many factors, including fuel metabolites, neu- 
rotransmitters and hormones. Among these hormones, 
prolactin (PRL) plays an important role in the matura- 
tion of the glucose sensing mechanisms. In fact, PRL 
treatment affects several physiological parameters of 
pancreatic B-cell, such as the glucose-induced reduction 
of K+ permeability [4], the glucose stimulation threshold 
[5], cell-to-cell coupling [5], [3H]thymidine incorporation 
[6] and the proliferation of j&cells in vitro [7]. 
GLUT2, the liver/j?cell glucose transporter, plays a 
key role in the glucose sensing apparatus [8]. One of the 
two goals of this study was to check if PRL treatment 
modifies glucose sensing in neonatal islets through an 
effect on GLUT2. 
G proteins are important modulators of pancreatic 
islet function. Pertussis toxin ADP-ribosylates G protein 
a subunits in pancreatic islet membranes [9,10]. Adre- 
nalin, somastotatin, galanin and prostaglandin inhibit 
insulin secretion through G protein modulated pathways 
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[9]. Somatostatin is used to regulate /?-cell function in 
human neonates with persistent hyperinsulinemic hypo- 
glycemia [111. CAMP augments insulin secretion [121 and 
is modulated by the cholera toxin sensitive G protein, 
Gs. Glucose induces an increase in phosphatidylinositol 
breakdown [ 121, as do the phospholipase C (PLC) isoen- 
zymes. Some PLC isoenzymes are under the control of 
G protein aq subunit, some under the control of G pro- 
tein Br subunits and some under the control of Pertussis 
Toxin sensitive G proteins [13-l 51. Any modification in 
these G protein modulated cascades could theoretically 
contribute to alter glucose sensing. The second goal of 
this study was to check if PRL treatment could modify 
the G protein-modulated cascades in neonatal islets. For 
that purpose we quantified some of the known G protein 
subunits by immunoblot analysis. 
We show here that PRL treatment of cultured neona- 
tal islets for 7-9 days increases the GLUT2 content in 
membranes of islets, but that the content of G protein 
subunits (ai2, ai3, ao, as, aq and 835 and 836) are 
unaltered by PRL treatment. 
2. Materials and methods 
2.1. Islets isolation and culture 
Islet from neonatal rats (2- to 36-h-old) were obtained as described 
[4] and maintained in culture at 37°C under 5% C02. The culture 
medium consisted of Eagle’s Minimum Essential Medium (Biofluids, 
Rockville, MD) supplemented with 2 mM glutamine, 10% fetal calf 
serum, 10 mM glucose, 100 IU/ml penicillin and 100 &ml streptomy- 
cin. Half of the plates also contained 2 ,@ml ovine PRL (highly puri- 
fied, isolated by Dr. AF Parlow, Harbor-University of California-Los 
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Angeles Medical Center and, kindly provided by the National 
Hormone and Pituitary Program of the NIDDK). Culture medium was 
changed every second day. After 7-9 days in culture, the medium was 
discarded and the islets were used for membrane preparation. 
2.2. Membrane preparation 
The islets from 4 different preparations were pooled and were sus- 
pended (10% v/v) in Tris-HCl 10 mM pH 7.9 containing DTT 1 mM, 
NaCl 10 mM, glycerol 20%, EGTA 1 mM, PMSF lOpM, leupeptin 0.1 
mg/ml, aprotinin 10 pug/ml, p-aminobenzamidine 1 mM, and soy bean 
trypsin inhibitor 1 mgfml; sonicated at 4°C (two pulses of 15 s) and 
centrifuged at 1000 x g for 10 min; and the supernatant was centrifuged 
25 min at 16,000 x g. The pellet was resuspended in the same buffer as 
above and alkylated with NEM as follows. 
2.3. NEM treatment 
Membranes were incubated for 10 min at 85°C in the presence of 
SDS 0.75% and DT’I 10 mM. NEM was then added to set the followine 
final concentrations: NEM 40 mM, SDS 0.6%, DTT 8mM and mem: 
brane protein slightly less than 1 m&ml. After 2 h at 4’C, I vol of 2 x 
Laemmli buffer 1161 containing 10% ~-mercaptoethanol was added. 
Protein concentration was checked with the Amido-black method fl7] 
prior to loading onto the gel. 
2.4. Immunobloting 
NEM-treated membrane proteins were resolved on a SDS-poly- 
acrylamide gel (0.1% SDS, 11% acrylamide, 0.08% bisacrylamide, 75 
$g protein~ane). Proteins were then transferred to PVDF membranes 
(Millipore, 150 mA 20 h) in Tris 25 mM glycine 192 mM buffer contain- 
ing 20% methanol. PVDF membranes were blocked for 2 h at room 
temperature in TTBS containing 2.5% gelatin and immunoblotted (20 
h at room temperature) with the antisera (GLUT2 antiserum 111000, 
SW antiserum l/200, other antisera were affinity purified and used at 
2-5 &ml in TTBS-gelatin 2.5%). The PVDF membranes were washed 
with TTBS and the ~tib~y-antigen complex was detected by r2’I- 
labeled protein A (Ame~ham, 0.2~C~ml in TTBS-gelatin 2.5% for 1-2 
h). Antibodies specific for G protein carboxy-terminal domains (see 
Table 1) were either purchased from NEM-DuPont or kindly donated 
by Dr P.K. Goldsmith and A.M. Spiegel, NIH, Bethesda, MD. 
3. Results 
We performed an immunoblot analysis of neonatal 
islets with an antibody specific for the liver/p-cell glucose 
transporter GLUT2. As can be seen from Fig. 1, this 
antibody labelled a 53 kDa band corresponding to 
GLUT2 in both control and PRL treated islets. PRL 
treatment induced a marked increase in GLUT2 content 
of neonatal islets (+86%), as appreciated by quantifica- 
tion with a phosphorimager, Molecular Dynamics). 
We also performed an immunoblot analysis of neona- 
tal islets membranes using antibodies specific for various 
G proteins subunits. As can be seen from Fig. 2, AS, 
specific for the G protein carboxy-terminal domain com- 
mon to ail and ai detected one single band of 40 kDA 
in both control and PRL-treated islets. This band corre- 
sponds to ai2, since it co-migrated with the lower band 
of brain cholate extract (data not shown), which has been 
identified as ai [18,19]. Moreover, LD, an antibody 
specific for an internal decapeptide of ail, failed to detect 
any 01 subunit in neonatal islets (data not shown). PRL 
treatment left ai content unchanged (Fig. 2). We also 
studied other G proteins subunits, namely ai3, CEO, as, czq 
and 835 and 836 with EC, GC2, RM, QL and SW anti- 
GLUT2 in neonatal islests 
GLUT2 * 
I + 
Fig. 1. Effect of PRL on GLUT2 protein measured by immunoblot. 
Neonatal islets were cultured for 7-9 days in Eagle’s Minimal Essential 
Medium in the absence or presence of 2 ,&ml of PRL. Neonatal islets 
protein (75 @lane) were analyzed by ~munoblotting with antiserum 
to GLUT2. This is one representative blot out of two. 
bodies. The G protein subunit contents detected by these 
antibodies were also unchanged by PRL treatment (Fig. 
2). 
Discussion 
The first step in glucose-induced insulin secretion is 
the entry of the sugar into the B-cells. This is mediated 
by the glucose transporter GLUT2, located at the ,&ccll 
plasma membrane. Alterations in the GLUT2 expression 
in j&cells have been implicated in the altered secretory 
response to glucose in rat NIDDM and IDDM models 
[20,21]. Furthermore, different tumoral cell lines, such 
p-TC, HIT and RIN cells with an abnormal response to 
glucose show reduced amounts of GLUT2, compared to 
normal /&cells (221. According to these authors, the ele- 
vated level of GLUTl, with a lower K, for hexose trans- 
port than GLUT2, in HIT cells could account for the 
abnormal secretory response to lower concentrations of 
glucose. 
Table 1 
G protein subunit antibodies 
Antibody Domain Sequence* G protein 
subunit 
AS 
EC 
:: 
GC2 
SW 
C-terminal 
C-terminal 
C-terminal 
C-terminal 
N-terminal 
C-terminal 
K~NLKDCGLF ail, ai 
KNNLKECGLY cd3 
RMHLRQYELL as 
QLNLKEYNLV aq, al 1 
GCTLSAEERAALERSK do 
SWDSFLKIWN 835,836 
* Single-letter amino acid code. 
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G-proteins subunits in neonatal islets 
AS EC GC2 
I 
supporting the view that the maturation of the glucose 
sensing mechanism, induced by this hormone is owing 
to, at least in part, an effect on GLUT2 expression. 
Recent data from this laboratory indicated that PRL 
potentiates the TPA/PKC-induced insulin secretion in 
the presence of glucose [4]. We investigated the possibil- 
I 
ity that PRL also affects this pathway upstream i.e. at G 
ai2+ a0 
protein aq and /3y subunits levels: aq is an activator of 
the PLCj?l, and By are activators of the PLCB2 [13-151. 
I Gaq is considered to be ubiquitous. We find that Gaq 
g$ $$ $i is also present in neonatal islets but unaffected by PRL 
I + I + 1+ treatment. Thus, the PRL effect on the PKC response is 
probably limited to a distal effect already described [4]. 
In conclusion these data clearly indicate that PRL 
treatment increases GLUT2 content in neonatal rat islets 
QL RM SW but does not alter the content of many G protein sub- 
I units. 
GLUT2 deficiency has been implicated in the low re- 
atill+ 
sponse to glucose from tumoral p-cells, in diabetes and 
in fasting. This is the first report implicating that 
GLUT2 could play a critical role in the normal matura- 
tion response during the neonatal period of develop- 
ment. 
I+ ;+ 
Fig. 2. Effect of PRL on ai2, ai3, ao, aqlll, as and /I35 and 836 G 
proteins subunits measured by immunoblot. Neonatal islets were cul- 
tured as indicated in the legend of Fig. 1. Islets proteins (75 pg/lane) 
were analyzed by immunobloting with antiserum AS, EC, GC2, QL, 
RM, SW to the above G proteins subunits, respectively. This is one 
representative blot of 2 or 3. 
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In neonatal islets the low secretory response to glucose 
has been ascribed to a diminished ATP production in 
response to a rise in glucose or leucine concentration 
compared to adult islets [23]. The recent findings that 
reduction in hexokinase IV activity may lead to some 
types of NIDDM [24] and that overexpression of yeast 
hexokinase in mouse p-cells decreases diabetes [25] sup- 
port the idea that a reduction in the hexokinase activity 
plays a role in certain types of diabetes. However, alter- 
ations in glucokinase activity were not observed in neo- 
natal islets [23]. On the contrary, at low glucose concen- 
trations, the glycolysis rate is higher in neonatal than 
adult islets. However, the glycolysis rate increases to a 
lesser extent in neonatal than adult islets in response to 
a rise in glucose concentration [23]. These observations 
together with the fact that insulin secretion, in response 
to intermediate glucose concentrations (5.6-l 1 .l mM), 
was even higher in neonatal than in adult islets [2] rather 
indicate that the poor secretory response to high glucose 
concentrations could be linked to alterations in the con- 
tent of glucose transporters of the GLUT2 type in islet 
cells. 
Our data show that PRL treatment increases the 
GLUT2 content in the membranes from neonatal islets 
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